Vcanbio Cell & Gene Engineering , Ltd Current Assets

The latest current assets for 600645.SS is $2.7B as of June 2026. That compares with $2.5B in the prior-year period — up 7.9% year over year. Investors often review this figure alongside Vcanbio Cell & Gene Engineering , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 600645.SS's current assets moved from $2.5B to $2.7B — a 7.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vcanbio Cell & Gene Engineering , Ltd's operating scale or balance-sheet position.

A current assets figure of $2.7B for 600645.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 600645.SS's current assets ($2.7B), review year-over-year change from $2.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Vcanbio Cell & Gene Engineering , Ltd's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.